
Nov 13, 2026 · 44 min
NVIDIA turmoil meets Anthropic’s IPO gamble and Moderna’s cancer bet
NVIDIA Without Jensen, Anthropic IPO Risks & Moderna’s Cancer Vaccine 11/12/26
The episode connects leadership and governance risk in major technology companies with investor uncertainty around AI markets and advances in personalized cancer treatment.
- 1Cramer weighs how Jensen Huang’s resignation allegations could affect NVIDIA’s governance, valuation, employees, and shareholders.
- 2Anthropic’s growth prospects face unresolved safety, liability, monetization, and lockup risks that could amplify IPO volatility.
- 3Moderna CEO Stéphane Bancel details personalized melanoma vaccines tailored to tumor mutations and the company’s broader pipeline.
Don't miss
Stéphane Bancel explains how Moderna’s personalized melanoma vaccine is designed around mutations found in an individual patient’s tumor.
The brief
Cramer opens with the fallout from Jensen Huang’s resignation at NVIDIA, weighing alleged misconduct, governance failures, export-related investigations, and consequences for shareholders and employees.
The episode’s consumer-business counterpoint is Kraft Heinz, where Steve Cahillane argues that scale, renewed investment, digital marketing, and innovation can revive legacy brands without splitting the company.
Anthropic offers a sharper market question: strong AI growth prospects and a large post-offering cash balance meet unresolved safety, liability, monetization, and staggered lockup risks.
The standout interview comes from Moderna CEO Stéphane Bancel, who explains how personalized melanoma vaccines are tailored to mutations in each patient’s tumor.
Cramer closes by returning to Huang’s alleged misconduct, framing the controversy as a breach of trust that reaches beyond NVIDIA’s technology and stock.
What was said on this episode
52 statements · 33 positive · 13 negative · 2 mixed · 4 neutral
Jensen Huang was a net liability to NVIDIA.
“Jensen Wang was more of a liability to the company he founded and ran than a positive.”
Listen at 0:32
NVIDIA’s board had no viable alternative to Huang’s departure.
“I don't think the board had any other choice.”
Listen at 1:37
NVIDIA will report a very strong quarter next week.
“The company reports next week, and I believe will be a huge quarter.”
Listen at 3:00
Huang’s departure reduces NVIDIA’s potential government-sanction risk.
“suddenly it is less likely now that Jensen has been cut loose.”
Listen at 3:29
Colette Kress will stabilize NVIDIA during the interim period.
“She will hold things together. well in the interim.”
Listen at 4:16
Kress’s appointment removes the need to sell NVIDIA over financial-scandal concerns.
“the idea that there is a financial scandal, the kind that makes you have to sell the stock, goes away.”
Listen at 4:21
NVIDIA’s investment ecosystem will generate returns after Anthropic’s IPO.
“the ecosystem that Jensen created with all these investments are now going to pay off.”
Listen at 4:45
NVIDIA investors should take some profits.
“you need to be sure you take at least some of those profits off the table.”
Listen at 5:06
Amazon may soon have a $50 billion semiconductor business.
“Amazon does have what may soon be a $50 billion semiconductor business.”
Listen at 5:44
Export restrictions could hurt NVIDIA’s business and reduce estimates.
“the investigations might lead to international export curtailments, which would hurt the business and lead to number cuts.”
Listen at 6:10
NVIDIA’s stock could decline further regardless of valuation.
“the stock could still go lower.”
Listen at 6:19
NVIDIA’s successor leadership will produce a different, not better, company.
“there won't be a better NVIDIA, just a different one.”
Listen at 6:58
Sunoco is attractive and investors should own or add to it.
“I think this thing's a great piece of paper. I think you're in good shape. Just own it. If it goes down to 6%, buy more.”
Listen at 8:31
Whirlpool may need new CEO leadership.
“maybe they need a kind of a CEO refresh”
Listen at 10:31
Heinz is performing very strongly in Brazil.
“Heinz in Brazil is doing phenomenally well.”
Listen at 13:23
Kraft Heinz expects substantially more growth opportunities in late 2027.
“the back half of 27, we start to see a lot more. A lot more opportunities to really get ourselves back to growth.”
Listen at 14:54
Kraft Mac and Cheese has returned to growth.
“And the brand is back to growth.”
Listen at 16:03
Kraft Heinz sold three months of cheesy ramen inventory in one week.
“We sold out three months worth of stock in a week.”
Listen at 16:12
Kraft Heinz’s high-protein chocolate Jell-O will be successful.
“I think is going to be a real hit.”
Listen at 16:47
Philadelphia cream cheese is among Kraft Heinz’s biggest share gainers this year.
“it's one of our biggest share gainers this year, Philadelphia cream.”
Listen at 17:17
Kraft Heinz retained scale and expects its $25 billion business to grow again.
“we were going to cut the company in half and become subscale. But instead, we're a $25 billion business that's going to be growing again.”
Listen at 18:08
Kraft Heinz is a strong company with a favorable future.
“It's a great company. It's an important company. It deserves a bright future.”
Listen at 19:04
Anthropic will have a very large cash balance after its IPO.
“the huge cash balance that Anthropic will have after its IPO.”
Listen at 20:29
Anthropic held $132 billion in cash and short-term investments at September’s end.
“the company had $132 billion in cash, cash equivalents, and short-term investments at the end of September.”
Listen at 20:34
Anthropic could raise approximately $100 billion in cash from its IPO.
“it could add around $100 billion in cash from next week's offering.”
Listen at 20:40
Claude writes 90% of Anthropic’s code contributions.
“90% of contributions to Anthropik's code base are actually being written by Claude at this point.”
Listen at 20:54
Claude-generated code improves Anthropic’s operational efficiency.
“It makes Anthropic more efficient”
Listen at 21:18
Anthropic has recently reduced prices for many models.
“Anthropic has been cutting prices for many of its models recently”
Listen at 21:34
Anthropic’s revenue growth remained strong after recent price cuts.
“Anthropix revenue growth remains strong in October after many of these price cuts went through.”
Listen at 21:51
Claude Code has substantial future growth potential.
“I still think Claude Code has plenty of growth ahead.”
Listen at 22:31
Cybersecurity could become Anthropic’s next major revenue use case.
“It might be cybersecurity, given how good Claude is at spotting code vulnerabilities.”
Listen at 23:11
Anthropic’s brand is built around AI safety.
“Anthropic has also built its brand around safety.”
Listen at 23:44
Anthropic may face additional regulatory constraints.
“I just worry that there will be more regulatory constraints for the company”
Listen at 24:28
A major cyberattack using an Anthropic model could create legal risk.
“Either that an anthropic model is used for some major cyber attack and that creates legal risk for the company”
Listen at 24:41
Regulatory and liability risks concern OpenAI more than Anthropic.
“these regulatory and liability risks are more of a concern for open AI than they are for anthropic”
Listen at 24:56
Anthropic’s IPO represents approximately 6% of shares outstanding.
“next week's offering represents around 6% of Anthropix shares outstanding.”
Listen at 25:23
Anthropic’s public float could reach approximately 7% on its first trading day.
“That would bring Anthropix float up to around 7% on the first day of trading.”
Listen at 25:38
Staggered share unlocks will put downward pressure on Anthropic’s stock.
“that's going to put downward pressure on Anthropoc.”
Listen at 26:04
Cramer is wary of buying Anthropic shares initially because of a potentially overheated opening.
“I'm wary of doing so. Why? Well, because I fear a hot open.”
Listen at 27:04
Moderna’s stock rose from $63 to above $174 in one day.
“Moderna was a $63 stock. The next day, it closed above $174”
Listen at 28:10
Moderna’s redesigned COVID vaccine has substantially improved side effects.
“the side effect is much better.”
Listen at 29:45
Moderna’s cancer vaccine is individually manufactured for each patient.
“We basically individualize. We make a product for one human at a time”
Listen at 31:32
The personalized vaccine is administered intramuscularly every three weeks for nine doses.
“It's injected in intramuscular every three weeks for nine doses.”
Listen at 31:43
Moderna’s melanoma treatment showed a 42% patient improvement versus Keytruda.
“we were able to show a 42% improvement for patients.”
Listen at 32:03
Moderna’s melanoma vaccine data improves over time.
“We show that the data improves over time.”
Listen at 32:17
Moderna expects its personalized cancer vaccine to become available in America in 2027.
“we should be able in 2027 to get the product available to Americans.”
Listen at 32:57
Moderna is studying its cancer vaccine across five tumor types, including lung cancer.
“we have studies ongoing in five different tumor types, including lung cancer.”
Listen at 33:47
Moderna expects kidney-cancer vaccine data by late 2026 or 2027.
“we should get data in kidney cancer pretty soon, either end of this year or next year.”
Listen at 34:18
Moderna may improve its cancer vaccine success rate through software refinement.
“we can potentially even improve that success rate”
Listen at 35:18
Tom Vault is a good investment choice despite its recent rise.
“I think it's a good call by you.”
Listen at 37:34
Bright Horizons is overvalued and should be avoided.
“Well, it's a very expensive stock, but that typically means to me the earnings aren't going to come through. I don't want you to mess around with it.”
Listen at 37:53
Cramer rejects Texas Pacific Land as an investment.
“I'm going to say no to Texas Pacific.”
Listen at 38:24
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.
Weekly email
State of the Pod, every Monday
The week's most-discussed names and stories from podcasts, with the moments behind them. Free, five minutes, unsubscribe in one click.